CDC报告：阿拉斯加百日咳全州暴发期间 DTaP疫苗对幼儿有效性达95.4%
美国疾病控制与预防中心（CDC）2026年10月15日发布的《发病率与死亡率周报》（MMWR）第75卷第40期（报告编号mm7540a1）刊登一项研究，评估白喉、破伤风类毒素和无细胞百日咳疫苗（DTaP）在2024年5月至11月阿拉斯加州全州百日咳暴发期间，对6个月至6岁儿童的保护效果。百日咳又称whooping cough，由百日咳杆菌引起。
研究以这次全州暴发期间的患病儿童与对照儿童为对象，其中完成三剂DTaP基础免疫的儿童被界定为完成接种组。结果显示，DTaP疫苗在该年龄段儿童中的有效性为95.4%。
研究同时发现，未接种疫苗的儿童感染百日咳的可能性是已接种儿童的13倍以上。这一对比来自同一暴发期、同一研究人群的病例与对照分析。
该报告为MMWR第75卷第40期的首篇报告，疫情发生地为阿拉斯加州，发生时间为2024年5月至11月，研究对象年龄为6个月至6岁。报告全文刊于CDC《发病率与死亡率周报》（来源：CDC MMWR）。
CDC: DTaP Vaccine 95.4% Effective in Young Children During Alaska Statewide Pertussis Outbreak
The U.S. Centers for Disease Control and Prevention (CDC) published a study in the Morbidity and Mortality Weekly Report (MMWR), Vol. 75, No. 40, on October 15, 2026 (report mm7540a1), evaluating the effectiveness of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) in children aged 6 months to 6 years during a statewide pertussis outbreak in Alaska from May to November 2024. Pertussis is also known as whooping cough and is caused by the bacterium Bordetella pertussis.
The study compared case-patients and control children from the statewide outbreak, with children who had received three DTaP doses in the primary series counted as fully vaccinated. It found DTaP vaccine effectiveness of 95.4% in this age group.
The study also found that unvaccinated children were more than 13 times as likely to be infected with pertussis as vaccinated children, based on the case-control analysis from the same outbreak period.
The report leads the October 15, 2026 issue of MMWR. The outbreak covered the state of Alaska between May and November 2024, and the study population was children aged 6 months to 6 years. Source: CDC MMWR, Vol. 75, No. 40 (mm7540a1).
发布：GSM·美国（发布链接）
图片来源：CDC Public Health Image Library / Public domain，via Wikimedia Commons（资料图：百日咳杆菌显微染色图）
GSM Global · 本篇英文版 English edition of this story
